Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 Bristol-Myers Squibb Co at Guggenheim Partners Healthcare Talks Oncology Days Transcript
Feb 12, 2021 / 05:00PM GMT
Release Date Price:
$59.97
(-0.11%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Thanks, everybody. Good afternoon. Thanks for joining us for a fireside chat session with Bristol-Myers Squibb. I'm Seamus Fernandez, Guggenheim's global biopharma analyst. We're joined today by Chris Boerner, Chief Commercialization Officer of Bristol-Myers Squibb. And obviously, we have a brief (inaudible) time here. I do apologize we're starting a touch late just because my Internet connection was unstable. So we're using the support of the global network at this point. So...
Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
Welcome to the world we live in.
Questions & Answers
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Exactly. So thanks again, everybody, for joining us. We do have a short time. So Bristol's breadth in oncology is obviously quite
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot